|
Conference/Events
| ShowHide Related Items >><< - 04/11/21
- Gracell reports long-term follow-up data on TruUCAR-enabled GC027
- 03/31/21
- Gracell signs agreement with Lonza to manufacture CAR-T product candidates
- 03/31/21
- Gracell enrolls first patient in Phase 1/2 study of GC007g for B-ALL
- 01/19/21
- Gracell's IND for acute lymphoblastic leukemia therapy approved in China
- 11/02/20
- LeMaitre CEO sells 93K shares of common stock
IONS Ionis Pharmaceuticals - 04/06/21
- Progenity, Ions enter agreement to evaluate ingestible oral biotherapies
- 04/05/21
- Ionis Pharmaceuticals initiates Phase 3 clinical trial of ION363
- 03/29/21
- Ionis Pharmaceuticals: Phase 2 study of IONIS-PKK-L met endpoints
- 03/22/21
- Ionis Pharmaceuticals trading resumes
TSHA Taysha Gene Therapies - 07:05 Today
- Taysha Gene Therapies acquires exclusive rights to AAV9 gene therapy program
- 03/09/21
- Taysha Gene Therapies announces collaboration to advance AAV gene therapies
- 02/09/21
- Taysha Gene Therapies announces multi-year collaborations for AAV gene therapies
- 01/26/21
- Taysha Gene Therapies appoints Timothy Douros as CLO, Tracy Porter as CPO
- 03/22/21
- Zealand Pharma jumps over 8% to $37.65 after FDA approval of Zegalogue
- 03/22/21
- Zealand Pharma announces FDA approval of Zegalogue injection in diabetes
- 03/22/21
- Zealand Pharma's dasiglucagon NDA approved by FDA
- 12/15/20
- Zealand Pharma: Dasiglucagon did not meet primary endpoint in Phase 3 trial
CLSD Clearside Biomedical - 03/02/21
- Clearside completes dosing in first cohort of Phase 1/2a trial of CLS-AX
- 02/16/21
- Clearside Biomedical announces presentation on CLS-AX
- 02/08/21
- Clearside featured in multiple data presentations at Macula Society meeting
- 01/12/21
- Clearside Biomedical enrolls first patients in Phase 1/2a trial of CLS-AX
- 04/11/21
- MEI Pharma reports preclinical data on Voruciclib ability to regulate MYC
- 01/04/21
- MEI Pharma expands Phase 1b study evaluating zandelisib
- 01/06/21
- Vaxcyte announces publication of preclinical PoC data of VAX-A1
- 12/22/20
- Vaxcyte appoints Andrew Guggenhime as president
- 03/23/21
- Evelo Biosciences announces collaboration with Abdul Latif Jameel Health
- 03/09/21
- Evelo Biosciences announces data from experimental model with EDP1815
- 03/09/21
- Evelo Biosciences announces expected 2021 milestones
- 02/16/21
- Evelo Biosciences appoints John Hohneker to board of directors
- 03/11/21
- Invacare falls -20.1%
- 03/11/21
- Invacare falls -16.8%
- 03/11/21
- Invacare falls -10.6%
- 10/30/20
- Invacare rises 12.4%
- 04/06/21
- BioSig announces purchase of PURE EP systems by hospital system
- 03/30/21
- BioSig Technologies awarded U.S. patent claims for noise-filtering technology
- 03/29/21
- BioSig Technologies issues shareholder letter with corporate update
- 03/04/21
- BioSig Technologies awarded patent claims for NeuroClear subsidiary
- 07:45 Today
- Cytokinetics announces preclinical data for CK-3773274
- 02/18/21
- Cytokinetics appoints Muna Bhanji to board of directors
- 01/13/21
- Cytokinetics announces dosing of first patient in Cohort 2 of Redwood-HCM
- 01/11/21
- Cytokinetics granted orphan drug designation for CK-3773274 in HCM
- 04/11/21
- Synlogic presents data from SYNB1891 Phase 1 trial at AACR Annual Meeting
- 03/24/21
- Synlogic's SYNB8802 achieves proof of mechanism, advances to Phase 1B
- 03/08/21
- Synlogic promotes Dr. Caroline Kurtz to Chief Development Officer
- 12/14/20
- Synlogic announces advancement of SYNB1891 to combination arm dosing
- 01/21/21
- Avidity Biosciences names W. Michael Flanagan, Ph.D. as Chief Technical Officer
- 01/08/21
- Avidity Biosciences reports 2021 pipeline updates, research pact with MyoKardia
- 01/13/21
- Castle Biosciences delivered 5,157 gene expression profile test reports in Q4
- 12/04/20
- Castle Biosciences publishes DecisionDx-Melanoma clinical use study
- 11/17/20
- Castle Biosciences announces publication of two studies in SKIN
- 11/12/20
- Castle Biosciences presents data for melanoma tests at ASDP
- 02/24/21
- Alamos Gold raises quarterly dividend 25% to 2.5c per share
- 12/18/20
- Alamos Gold announces renewal of Normal Course Issuer Bid
- 12/09/20
- Alamos Gold provides 2021 production and operating guidance
- 10/28/20
- Alamos Gold raises quarterly dividend to 2c per share from 1.5c per share
- 04/08/21
- Cara Therapeutics to replace MTS Systems in S&P 600 at open on 4/8
- 04/05/21
- Cara Therapeutics to replace MTS Systems in S&P 600 at open on 4/8
- 03/30/21
- VFMCRP, Cara Therapeutics announces EMA acceptance of difelikefalin MAA
- 03/08/21
- Vifor Pharma, Cara Therapeutics receive priority review for Korsuva NDA
- 03/12/21
- Comfort Systems USA CEO sells 42K shares of common stock
- 02/25/21
- Comfort Systems USA raises quarterly dividend to 11.5c from 11c per share
- 01/05/21
- Comfort Systems USA to acquire Tennessee Electric Company
- 12/11/20
- Comfort Systems USA appoints Trent McKenna as COO
- 03/16/21
- Iterum Therapeutics appoints Beth Hecht to board of directors
- 03/12/21
- Iterum Therapeutics says oral suplopenem NDA has PDUFA date July 25
- 03/12/21
- Iterum Therapeutics expects cash to fund operations into 1H23
- 02/01/21
- Iterum Therapeutics engages EVERSANA to support oral sulopenem launch
- 04/01/21
- Lantern Pharma announces collaboration with Johns Hopkins on LP-184
- 03/17/21
- Lantern Pharma files seven patent applications on anticancer agent
- 01/04/21
- Lantern Pharma launches Antibody Drug Conjugate program
- 12/17/20
- Lantern Pharma announces collaboration with Johns Hopkins on LP-184
- 03/03/21
- Ocugen, Bharat Biotech announce Phase 3 interim results of COVAXIN
- 02/23/21
- Ocugen granted orphan medicinal product designation for OCU400 by EMA
- 02/08/21
- Ocugen Inc trading resumes
- 02/08/21
- Ocugen Inc trading halted, volatility trading pause
- 04/08/21
- uniQure announces publications of preclinical data for AMT-130
- 04/05/21
- uniQure completes enrollment in first cohort of phase I/II trial of AMT-130
- 03/29/21
- uniQure announces findings from case of HCC in Hemophilia B gene therapy program
- 03/01/21
- uniQure expects cash to fund operations into 2H22
- 07:17 Today
- Shattuck Labs highlights preclinical data for SL-9258 and GLADEN at AACR 2021
- 03/16/21
- Shattuck Labs appoints Andrew Neill as CFO
- 11/11/20
- Shattuck Labs announces preclinical PoC study on GADLEN platform
- 01/06/21
- Viking Therapeutics names Greg Zante as CFO, Marianne Mancini as COO
- 02/03/21 Citi
- Gracell initiated with a Buy at Citi
- 02/02/21 Jefferies
- Gracell initiated with a Buy at Jefferies
- 02/02/21 Wells Fargo
- Gracell initiated with an Overweight at Wells Fargo
- 02/02/21 Piper Sandler
- Gracell initiated with an Overweight at Piper Sandler
- 02/26/21 Barrington
- LeMaitre price target raised to $49 from $47 at Barrington
- 02/12/21
- Fly Intel: Top five analyst initiations
- 02/12/21 KeyBanc
- LeMaitre initiated with a Sector Weight at KeyBanc
- 02/11/21 KeyBanc
- LeMaitre initiated with a Sector Weight at KeyBanc
IONS Ionis Pharmaceuticals - 03/29/21 Piper Sandler
- Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
- 03/29/21 RBC Capital
- PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
- 03/23/21 Truist
- Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
- 03/23/21 BMO Capital
- Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
TSHA Taysha Gene Therapies - 03/04/21 Chardan
- Taysha Gene Therapies price target raised to $60 from $45 at Chardan
- 02/23/21 William Blair
- William Blair starts Taysha with Outperform, $46 fair-value estimate
- 02/23/21 William Blair
- William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
- 02/23/21 William Blair
- Taysha Gene Therapies initiated with an Outperform at William Blair
CLSD Clearside Biomedical - 03/02/21 Roth Capital
- Clearside enrollment speed 'encouraging,' says Roth Capital
- 12/03/20 Roth Capital
- Clearside platform validated by Janssen deal, says Roth Capital
- 08/06/20 Roth Capital
- Investors should buy 'highly undervalued' Clearside, says Roth Capital
- 06/19/20 Roth Capital
- Clearside Biomedical abstracts highlight strength, says Roth Capital
- 10/12/20 Brookline
- MEI Pharma initiated with a Buy at Brookline
- 09/22/20 Alliance Global Partners
- MEI Pharma initiated with a Buy at Alliance Global Partners
- 07/06/20 SunTrust
- MEI Pharma price target lowered to $12 from $16 at SunTrust
- 05/29/20
- Fly Intel: Top five analyst initiations
- 07/16/20 Wells Fargo
- Sutro Biopharma initiated with an Overweight at Wells Fargo
- 07/07/20
- Fly Intel: Top five analyst initiations
- 07/07/20 BofA
- Vaxcyte initiated with a Buy at BofA
- 07/07/20 Jefferies
- Vaxcyte initiated with a Buy at Jefferies
- 07:52 Today Jefferies
- Jefferies upgrades Evelo Biosciences to Buy on increased microbiome momentum
- 04:50 Today Jefferies
- Evelo Biosciences upgraded to Buy from Hold at Jefferies
- 03/12/21 Chardan
- Evelo Biosciences price target raised to $15 from $10 at Chardan
- 01/25/21 JMP Securities
- Evelo Biosciences price target raised to $36 from $27 at JMP Securities
- 03/11/21 Wolfe Research
- Cytokinetics initiated with an Outperform at Wolfe Research
- 02/18/21 Barclays
- Cytokinetics initiated with an Overweight at Barclays
- 01/20/21 H.C. Wainwright
- Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
- 12/28/20 Oppenheimer
- Amgen price target lowered to $266 from $274 at Oppenheimer
- 03/25/21 SVB Leerink
- Synlogic price target raised to $15 from $10 at SVB Leerink
- 03/18/21 JonesTrading
- Synlogic initiated with a Buy at JonesTrading
- 01/13/21 Chardan
- Chardan doubles Synlogic target to $10, names top 2021 pick
- 09/18/20 Chardan
- Seres Therapeutics downgraded to Neutral from Buy at Chardan
- 07/07/20 Cowen
- Avidity Biosciences initiated with an Outperform at Cowen
- 07/07/20 SVB Leerink
- Avidity Biosciences initiated with an Outperform at SVB Leerink
- 07/07/20 Cowen
- Avidity Biosciences initiated with an Outperform at Cowen
- 07/07/20 Wells Fargo
- Avidity Biosciences initiated with an Overweight at Wells Fargo
- 03/09/21 Baird
- Castle Biosciences price target lowered to $82 from $87 at Baird
- 02/03/21 KeyBanc
- Castle Biosciences price target raised to $90 from $70 at KeyBanc
- 01/26/21 Canaccord
- Castle Biosciences price target raised to $84 from $80 at Canaccord
- 01/15/21 SVB Leerink
- Castle Biosciences price target raised to $80 from $70 at SVB Leerink
- 02/10/21 JPMorgan
- Alamos Gold initiated with a Neutral at JPMorgan
- 02/08/21 CIBC
- Alamos Gold price target lowered to C$16 from C$19.25 at CIBC
- 02/02/21 National Bank
- Alamos Gold price target lowered to C$14.50 from C$15.50 at National Bank
- 01/11/21 National Bank
- Alamos Gold price target lowered to C$15.50 from C$16 at National Bank
- 12/29/20 H.C. Wainwright
- H.C. Wainwright reiterates $33 target on Cara after new drug filing
- 10/20/20 H.C. Wainwright
- Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
- 04/22/20 Cantor Fitzgerald
- Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
- 04/21/20 H.C. Wainwright
- Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
- 07/29/20 DA Davidson
- Comfort Systems USA price target raised to $45 from $32 at DA Davidson
- 04/29/20 DA Davidson
- Comfort Systems USA downgraded to Neutral from Buy at DA Davidson
- 04/29/20 DA Davidson
- Comfort Systems USA downgraded to Neutral from Buy at DA Davidson
- 04/20/20 Sidoti
- Comfort Systems USA downgraded to Neutral from Buy at Sidoti
- 03/15/21 H.C. Wainwright
- Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
- 12/24/20 H.C. Wainwright
- Iterum CSO resignation 'somewhat troubling,' says H.C. Wainwright
- 06/16/20 H.C. Wainwright
- Iterum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- 06/02/20 RBC Capital
- Iterum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- 08/10/20 ThinkEquity
- Lantern Pharma initiated with a Buy at ThinkEquity
- 07/28/20 Colliers
- Drug 'rescuer' Lantern Pharma started at Buy at Colliers
- 07/28/20 Colliers
- Lantern Pharma initiated with a Buy at Colliers
- 03/31/21
- Ocugen participates in a conference call with Cantor Fitzgerald
- 03/16/21 Roth Capital
- Covaxin chances of U.S. approval now increased, says Roth Capital
- 03/04/21 Roth Capital
- Ocugen price target raised to $10 from $9 at Roth Capital
- 03/04/21 Roth Capital
- Roth boosts Ocugen target after partnered vaccine shows 'broad' efficacy
- 04/01/21
- Fly Intel: Top five analyst upgrades
- 04/01/21 Mizuho
- uniQure upgraded to Buy on favorable risk/reward at Mizuho
- 04/01/21 Mizuho
- uniQure upgraded to Buy from Neutral at Mizuho
- 03/29/21 H.C. Wainwright
- uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
- 01/20/21 Citi
- Shattuck Labs price target raised to $75 from $36 at Citi
- 01/11/21 Evercore ISI
- Shattuck Labs initiated with an Outperform at Evercore ISI
- 11/03/20 Needham
- Shattuck Labs initiated with a Buy at Needham
- 11/03/20 Citi
- Shattuck Labs initiated with a Buy at Citi
- 02/18/21 Chardan
- Chardan trims Viking Therapeutics target to $19 as COVID pushes out Voyage data
- 09/11/20 B. Riley FBR
- Viking Therapeutics price target raised to $15 from $12 at B. Riley FBR
- 09/01/20 BTIG
- Viking Therapeutics price target raised to $12 from $9 at BTIG
- 08/30/20 Chardan
- Viking Therapeutics price target raised to $20 from $15 at Chardan
- 10/29/20
- LeMaitre sees Q4 EPS 94c-$1.04, consensus 22c
- 10/29/20
- LeMaitre reports Q3 EPS 37c, consensus 19c
IONS Ionis Pharmaceuticals - 02/24/21
- Ionis Pharmaceuticals sees 2021 revenue over $600M, consensus $781.31M
- 02/24/21
- Ionis Pharmaceuticals reports Q4 EPS ($2.44), consensus 28c
- 11/04/20
- Ionis Pharmaceuticals reports Q3 EPS (22c), consensus (9c)
TSHA Taysha Gene Therapies - 03/03/21
- Taysha Gene Therapies reports Q4 EPS (12c), consensus (37c)
- 03/11/21
- Zealand Pharma sees 2021 commercial revenue DKK220M, plus or minus 10%
- 03/11/21
- Zealand reports 2020 revenue DKK353.3M vs. DKK41.3M last year
- 11/12/20
- Zealand Pharma expects 2020 revenue for V-Go sales DKK150M-DKK175M
- 11/12/20
- Zealand Pharma reports Q3 revenue DKK56.5M vs. DKK9.9M last year
CLSD Clearside Biomedical - 11/10/20
- Clearside Biomedical reports Q EPS , consensus
- 02/04/21
- MEI Pharma reports Q2 EPS (16c), consensus (13c)
- 11/10/20
- MEI Pharma reports Q1 EPS (2c), consensus (8c)
- 03/29/21
- Vaxcyte reports Q4 EPS (41c), consensus (54c)
- 03/09/21
- Evelo Biosciences reports Q4 EPS (62c), consensus (53c)
- 10/29/20
- Evelo Biosciences reports Q3 EPS (45c), consensus (50c)
- 02/10/21
- Invacare sees FY21 constant currency net sales growth of 4%-7%
- 02/10/21
- Invacare reports Q4 adjusted EPS (10c), consensus (20c)
- 10/29/20
- Invacare raises FY20 revenue view to at least $840M from $810M-$840M
- 10/29/20
- Invacare reports Q3 adjusted EPS (10c), consensus (18c)
- 11/04/20
- Cytokinetics reports Q3 EPS (5c), consensus (34c)
- 03/25/21
- Synlogic reports Q4 EPS (39c), consensus (40c)
- 11/05/20
- Synlogic reports Q3 EPS (36c), consensus (47c)
- 03/15/21
- Avidity Biosciences reports Q4 EPS (43c), consensus (34c)
- 11/10/20
- Avidity Biosciences reports Q3 EPS (31c), consensus (37c)
- 03/08/21
- Castle Biosciences reports Q4 EPS (23c), consensus (12c)
- 11/09/20
- Castle Biosciences reports Q3 EPS (23c), consensus (11c)
- 10/28/20
- Alamos Gold reports Q3 EPS C$0.15 vs. C$0.06 last year
- 11/09/20
- Cara Therapeutics reports Q3 EPS (35c), consensus (60c)
- 02/25/21
- Comfort Systems USA reports Q4 EPS 99c excluding benefit, consensus 83c
- 10/26/20
- Comfort Systems USA sees FY20 results 'significantly' surpassing FY19 results
- 10/26/20
- Comfort Systems USA reports Q3 EPS $1.36, consensus $1.08
- 03/12/21
- Iterum Therapeutics reports Q4 EPS (11c), consensus (19c)
- 03/10/21
- Lantern Pharma reports Q4 EPS (47c), consensus (45c)
- 12/15/20
- Lantern Pharma announces data that substantiates BBB for LP-184
- 03/18/21
- Ocugen reports 2020 EPS (31c), consensus (33c)
- 11/06/20
- Ocugen reports Q3 EPS (7c), consensus (2c)
- 03/01/21
- uniQure reports 2020 EPS ($2.81), consensus ($1.25)
- 10/27/20
- uniQure reports Q3 EPS ($1.21) vs. (58c) last year
- 03/15/21
- Shattuck Labs reports Q4 EPS (31), consensus (39c)
- 11/13/20
- Shattuck Labs reports Q3 EPS ($1.54), consensus (34c)
- 02/17/21
- Viking Therapeutics reports Q4 EPS (15c), consensus (15c)
- 10/28/20
- Viking Therapeutics reports Q3 EPS (13c), consensus (15c)
|